Valbenazine did not meet the primary endpoint in Phase IIb T-Force GOLD study to treat Tourette syndrome.- Neurocrine Biosciences

Neurocrine Biosciences announced topline data from the Phase IIb T-Force GOLD study demonstrating that valbenazine did not meet the primary endpoint as assessed by the Yale Global Tic Severity Scale (YGTSS) in children and adolescents with moderate to severe Tourette syndrome. The types of treatment emergent adverse events observed in this trial were consistent with those seen in other valbenazine studies.

The company will further analyze the data to determine the next steps for valbenazine in Tourette syndrome.